Delivery Order SPE2DB20D3103-SPE2DB25FP3S4
Award Date 7/2/25
Potential Completion Date 7/24/25
Potential Value $17K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $72,034 firm fixed-price delivery order from the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. This competitively awarded contract, with no set-aside designation, is scheduled for completion by May 15, 2025. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of XOLAIR 150 mg/ml syringes, with a contract ceiling value of $2,161.02 and a completion date of June 26, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes valued at $2,881.36, with an ultimate completion date of August 8, 2025. This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody used in the treatment of moderate-to-severe...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $14,406.80 for XOLAIR 150 mg/ml syringes on June 2, 2025, with completion expected by June 24, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order under the Defense Logistics Agency Medical Supply Chain. The award is a child contract derived from AmerisourceBergen's larger Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,881.40 by the Defense Logistics Agency for XOLAIR 150 mg/ml syringes. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by May 15, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a...
- The Defense Logistics Agency awarded a delivery order valued at $7,203.40 to AmerisourceBergen Drug Corp for XOLAIR 150 MG/1.2 ML Powder vials under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of August 11, 2025. This is a non-set-aside, competitively awarded delivery order that will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a monoclonal antibody therapy commonly used for treating...
- The Defense Logistics Agency awarded a delivery order valued at $3,601.70 to AmerisourceBergen Drug Corp for XOLAIR 150 mg/mL syringes. This competitively awarded, firm fixed-price contract was issued on July 23, 2025, with an ultimate completion date of August 13, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. XOLAIR (omalizumab) is a monoclonal antibody...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order for XOLAIR 150 mg/ml syringes valued at $108,051.00 under a firm fixed-price contract. This non-set-aside award was issued on July 31, 2025, with an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. XOLAIR is a biologic medication used to treat moderate-to-severe allergic asthma and other...
- The Defense Logistics Agency awarded a $34,576.32 delivery order to AmerisourceBergen Drug Corp for XOLAIR 150 mg/ml syringes, with a completion date of August 22, 2025. This is a firm fixed price, non-set-aside contract awarded on August 1, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. XOLAIR (omalizumab) is a biologic medication used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, representing a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,440.70 for XOLAIR 150 mg/mL syringes, with an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract representing a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania....